Guerbet announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the granting of marketing authorization for Elucirem (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 and over for contrast-enhanced MRI.

The European Commission is expected to issue its decision by the end of 2023.
In September 2022, Elucirem was approved by the US Food and Drug Administration.

As a reminder, Elucirem (Gadopiclenol) is a contrast agent indicated for use in adults and children aged 2 and over for magnetic resonance imaging (MRI).

Copyright (c) 2023 CercleFinance.com. All rights reserved.